Richard B. Lanman

Dr. Lanman is a serial entrepreneur who has led medical affairs for three biotechnology companies from seed stage to public.

Most recently, as Global Chief Medical Officer at Guardant Health, Inc., Dr. Lanman planned and executed the research studies, publications, and physician education in oncology genomics required to obtain broad insurance coverage, incorporation in clinical guidelines, and FDA approvals and clearances in record time. A team builder, he engaged premier academic centers and pharmaceutical company strategic partners to accelerate translational research. Dr. Lanman served in a similar capacity as the Chief Medical Officer of Veracyte, a developer of minimally invasive cytology-based genomics tests in endocrinology and pulmonology. Previously, he was Chief Medical Officer for two cardiovascular biodiagnostics companies, diaDexus and Atherotech, which underwent reverse IPO and private sale, respectively.